

1 **Evolving Virulence? Decreasing COVID-19 Complications among Massachusetts**

2 **Healthcare Workers: A Cohort Study**

3 Running title: COVID-19 Complications Decreasing among HCWs

4

5 Authors: Fan-Yun Lan, Robert Filler, Soni Mathew, Eirini Iliaki, Rebecca Osgood, Lou

6 Ann Bruno-Murtha, Stefanos N. Kales

7

8 Author affiliations: Harvard University T.H. Chan School of Public Health, Boston,

9 Massachusetts, USA (F-Y Lan, R. Filler, S.N. Kales); National Cheng Kung University

10 Hospital, Tainan, Taiwan (F-Y Lan); Cambridge Health Alliance, Harvard Medical

11 School, Cambridge, Massachusetts, USA (S. Mathew, E. Iliaki, R. Osgood, L.A.

12 Bruno-Murtha, S.N. Kales)

13

14 Corresponding author: Stefanos N. Kales, MD, MPH

15 Occupational Medicine, Cambridge Health Alliance, Macht Building 427

16 1493 Cambridge Street, Cambridge, MA 02139

17 Tel. 617/665-1580 Fax. 617/665-1672

18 E-mail: [skales@hsph.harvard.edu](mailto:skales@hsph.harvard.edu)

19 **Abstract—word count: 49**

20 The hypothesis of attenuating SARS-CoV-2 virulence has been raised. We examined  
21 the temporal distribution of COVID-19 complications (ER visits, hospitalization,  
22 intubation/code, and/or death) among healthcare workers in one system that applied  
23 uniform screening criteria throughout the research period, and found the complication  
24 rate significantly decreased after April 15, 2020.

25

26

27 **Text—word count: 797 (not including Acknowledgments and the author’s**  
28 **biographical sketch)**

29 There is limited research investigating possible changes in SARS-CoV-2  
30 virulence. Existing evidence shows a decreasing case-fatality rate in the United States  
31 (1). However, in relation to virulence, this statistic may be biased by improved clinical  
32 acumen as well as increased testing detecting more asymptomatic and  
33 paucisymptomatic cases. An Italian study has demonstrated lower nasopharyngeal viral  
34 load in the later phase of the pandemic (2). In addition, attenuated SARS-CoV-2  
35 variants have been reported (3,4). Therefore, we investigated the temporal distribution  
36 of COVID-19 complications among healthcare workers (HCWs) to determine if the  
37 clinical case severity decreased over time.

38 This retrospective cohort study examined adult HCWs from a Massachusetts  
39 community healthcare system using a uniform COVID-19 protocol to screen and test  
40 employees since the initial outbreak in March 2020. Inclusion criteria were: 1)  
41 COVID-19 triage via the occupational health “hotline” and a documentation of a  
42 positive SARS-CoV-2 viral assay between March 9 and July 8, 2020, or 2) any  
43 untriaged employee with a complication due to COVID-19 subsequently confirmed by  
44 the system’s occupational health department. Since the initial outbreak, the

45 occupational health “hotline” phone-interviewed HCWs with any concerns regarding a)  
46 travel; b) potential contact with a COVID-19-positive/suspect person; or c) possible  
47 viral symptoms, and referred HCWs for a nasopharyngeal SARS-CoV-2 RT-PCR assay  
48 when clinically indicated. HCWs tested outside the system sent in their PCR results for  
49 confirmation. All cases were contacted regularly and followed until July 31, 2020 for  
50 any complication, including: ER (Emergency Room) visit, hospitalization,  
51 intubation/code, and/or death. Detailed data acquisition, de-identification and ethical  
52 statement have been published previously (5).

53 Because Massachusetts has used April 15<sup>th</sup> as the date to measure improvements  
54 from the states’ pandemic peak (Figure) (6), we defined the cases triaged up to April 15,  
55 2020, as “early”, and those afterwards as “late”. We also included as early, any  
56 untriated death occurring within 18 days of April 15, 2020 based on the median time  
57 from infection onset to death (7,8). Sensitivity analysis was done by restricting the  
58 study population to only triaged COVID-19 cases.

59 We used the t-test or Wilcoxon rank sum test, as appropriate, to compare  
60 continuous variables, and chi-square test or the Fisher’s exact test, as appropriate, for  
61 categorical variables. Logistic regression models were built for multivariate adjustment.  
62 The analyses were performed using R software (version 3.6.3), two-sided and with a

63  $P$ -value  $< 0.05$  considered statistically significant.

64       The temporal distribution of incident COVID-19 cases in the study population  
65 showed a pattern similar to that statewide (6) (Figure). A total of 166 eligible cases were  
66 identified in the study period: 98 early and 68 late. There were no significant  
67 differences between early and late cases regarding age, sex, race, residential  
68 community attack rates (6), and number of presenting symptoms. Cough was more  
69 frequently reported in early cases (66% vs. 50%,  $P=0.04$ ), while headache was more  
70 frequently reported later (42% vs. 60%,  $P=0.03$ ). There were a total of 13 cases with  
71 any complications in the database, comprised of 12 early cases and one late case  
72 ( $P=0.02$ ). Ten cases experienced hospitalization or death (9 early vs. 1 late,  $P<0.05$ ).  
73 Three cases underwent intubation or a code (all early cases) and two of these HCWs  
74 died (Table). After adjusting for age, sex, and race, early cases had increased odds  
75 ratios (ORs) in any complication(s) (10.3, 95%CI: 1.7-199.9), and  
76 hospitalization/death (6.2, 95%CI: 1.0-122.5).

77       In the sensitivity analysis, we excluded one COVID-19 death on April 29, who did  
78 not undergo triage and had an unknown date of symptom onset. The results remained  
79 significant regarding early versus late total complications: 11.3% (11/97) and 1.5%  
80 (1/68) ( $P=0.02$ ).

81           Our study provides epidemiologic support for the hypothesis of possible  
82   attenuated viral virulence (2-4) regarding clinical severity. We found cases infected  
83   later in the pandemic were less likely to sustain a complication. Later cases were also  
84   more likely to have headache, which may portend a more favorable course (9). The  
85   current study has several strengths. First, we used uniform screening protocols and  
86   testing criteria for all employees throughout the study period, minimizing bias from  
87   younger and less symptomatic cases detected as testing became more widespread. In  
88   fact, we observed that the age, sociodemographic characteristics and presenting  
89   symptoms of early and late cases were in fact quite similar, and the results remained  
90   significant after adjusting for these potential confounders. Second, the similar temporal  
91   epidemic pattern between the HCWs and the general population implies possible  
92   generalizability to other working populations. Nonetheless, the present study had  
93   limited sample size and HCWs' underlying medical conditions were unavailable.  
94   Additional investigations are warranted in larger populations with adjustment for  
95   underlying comorbidities, other factors predisposing to complications and clinical  
96   management. Second, although our results implied headache may be associated with  
97   more favorable outcomes, we cannot exclude the possibility that headache is more  
98   likely to be perceived by patients with mild illness.

99 Dr. Lan is a PhD candidate in Population Health Sciences at Harvard University,

100 USA. He is also an occupational physician at National Cheng Kung University

101 Hospital, Taiwan. His primary research interest involves environmental and

102 occupational medicine and epidemiology.

103 **Acknowledgments**

104 All authors declare no competing interest, and none of the authors receives

105 funding toward the present study.

106

107     **References**

- 108     1.     Our World in Data. Statistics and research: mortality risk of COVID-19. [cited  
109             2020 Aug 16].  
110             [https://ourworldindata.org/mortality-risk-covid#how-did-confirmed-deaths-an](https://ourworldindata.org/mortality-risk-covid#how-did-confirmed-deaths-and-cases-change-over-time)  
111             [d-cases-change-over-time](https://ourworldindata.org/mortality-risk-covid#how-did-confirmed-deaths-and-cases-change-over-time)
- 112     2.     Clementi N, Ferrarese R, Tonelli M, Amato V, Racca S, Locatelli M, et al.  
113             Lower nasopharyngeal viral load during the latest phase of COVID-19  
114             pandemic in a Northern Italy University Hospital. Clin Chem Lab Med. 2020;  
115             Epub ahead of print. doi: 10.1515/cclm-2020-0815
- 116     3.     Lau SY, Wang P, Mok BW, Zhang AJ, Chu H, Lee AC, et al. Attenuated  
117             SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerg Microbes  
118             Infect. 2020;9:837–842. doi:10.1080/22221751.2020.1756700
- 119     4.     Benvenuto D, Angeletti S, Giovanetti M, Bianchi M, Pascarella S, Cauda R, et  
120             al. Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural  
121             Protein 6 (NSP6) could affect viral autophagy. J Infect. 2020;81:e24–e27. doi:  
122             10.1016/j.jinf.2020.03.058
- 123     5.     Lan FY, Filler R, Mathew S, Buley J, Iliaki E, Bruno-Murtha LA, et al.  
124             COVID-19 symptoms predictive of healthcare workers' SARS-CoV-2 PCR

- 125 results. PLoS One. 2020;15:e0235460. doi:10.1371/journal.pone.0235460
- 126 6. Massachusetts Department of Public Health. COVID-19 response reporting.
- 127 [cited 2020 Aug 16].
- 128 <https://www.mass.gov/info-details/covid-19-response-reporting>
- 129 7. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of
- 130 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a
- 131 single-centered, retrospective, observational study. Lancet Respir Med.
- 132 2020;8:475–481. doi:10.1016/S2213-2600(20)30079-5
- 133 8. Wilson N, Kvalsvig A, Barnard LT, Baker MG. Case-Fatality risk estimates for
- 134 COVID-19 calculated by using a lag time for fatality. Emerg Infect Dis.
- 135 2020;26:1339–1441. doi: 10.3201/eid2606.200320
- 136 9. Greb E. Headache may predict clinical evolution of COVID-19. Neurology
- 137 Reviews [Internet]. 2020 Jun [cited 2020 Aug 16].
- 138 [https://www.mdedge.com/neurology/article/224253/headache-migraine/heada](https://www.mdedge.com/neurology/article/224253/headache-migraine/headache-may-predict-clinical-evolution-covid-19)
- 139 [che-may-predict-clinical-evolution-covid-19](https://www.mdedge.com/neurology/article/224253/headache-migraine/headache-may-predict-clinical-evolution-covid-19)
- 140
- 141

142 **Table. Early and late COVID-19 cases' clinical characteristics and complication rates**

	Early (thru 15 April) (n=98)	Late (16 April–9 July) (n=68)	P-value
Age (n=166)	43.1 (12.9)	41.5 (11.9)	0.440
Sex (n=159)			0.944
Female	70 (71.4%)	46 (67.6%)	
Male	25 (25.5%)	18 (26.5%)	
Race (n=156)			0.517
Non-Hispanic white	38 (38.8%)	18 (26.5%)	
African American	33 (33.7%)	27 (39.7%)	
Hispanic	18 (18.4%)	14 (20.6%)	
Others	5 (5.1%)	3 (4.4%)	
Cumulative community attack rate* (as of June 3) (n=156)	1723.7 (1214.2–3393.3)	1802.8 (1634.5–2330.2)	0.883†
Total number of symptoms (n=165)	4 (3–5)	4 (2–5)	0.529†
No symptom	4 (4.1%)	4 (5.9%)	0.718‡
Fever	50 (51.0%)	25 (36.8%)	0.086
Cough	65 (66.3%)	34 (50.0%)	<b>0.042</b>
Dyspnea	13 (13.3%)	12 (17.6%)	0.598
Myalgia	48 (49.0%)	34 (50.0%)	0.999
Malaise	51 (52.0%)	29 (42.6%)	0.272
Nasal symptoms	33 (33.7%)	28 (41.2%)	0.439
GI symptoms	26 (26.5%)	15 (22.1%)	0.609
Rash	3 (3.1%)	1 (1.5%)	0.644‡
Anosmia/Ageusia	14 (14.3%)	18 (26.5%)	0.085
Headache	41 (41.8%)	41 (60.3%)	<b>0.034</b>
Sore throat	41 (41.8%)	20 (29.4%)	0.129
Any complication(s) (n=166)	12 (12.2%)	1 (1.5%)	<b>0.016‡</b>
ER visit	12 (12.2%)	1 (1.5%)	<b>0.016‡</b>
Hospitalization/death§	9 (9.2%)	1 (1.5%)	<b>0.049‡</b>
Intubation/coded§	3 (3.1%)	0	0.270‡
Death	2 (2.0%)	0	0.513‡

143 Mean (SD) for age. Median (Q1-Q3) for cumulative community attack rate and total number of symptoms. Count (%)

144 for other variables.

145 Nasal symptoms include runny, sneezing, congestion, and sinus symptoms. GI (Gastrointestinal) symptoms include

146 nausea/ vomiting/ diarrhea. ER, Emergency Room.

147 \*Community rates based on Massachusetts data for each healthcare worker's town of residence.

148 †Wilcoxon rank sum test

149 ‡Fisher's exact test

150 §Patient coded and died in an Emergency Department.

151

152 **Figure. Temporal Distribution of Incident Confirmed COVID-19 Cases from**

153 **March 5 to July 9, 2020 in (A) the Study Population and (B) Massachusetts**

154 **Statewide.**

155

156 Bars indicate the absolute number of daily cases, and the red line denotes the 7-day

157 average of new cases.

